Results

1–10 of 46 results for Dry AMD

Improving Vision in Dry AMD: Matching Mechanism With the Right Patient Population and Stage of Disease
Baruch D. Kuppermann, MD, PhD
Annual Meeting Talks
2023
Multiwavelength Photobiomodulation Significantly Reduces Risk for Vision Loss and Onset of Geographic Atrophy in Dry Age-Related Macular Degeneration
Eleonora Lad, MD, PhD
Annual Meeting Talks
2024
Delayed Near Infrared Analysis Identifies Novel Features of Nonexudative Dry Age-Related Macular Degeneration in a Natural History Study: Baseline Findings
Shelley Boyd, MD, FRCS(C)
Annual Meeting Talks
2024
LIGHTSITE IIIB: A Prospective, Multi-Center Extension Study to Assess the Long-Term Safety and Efficacy of Photobiomodulation in Dry Age-Related Macular Degeneration
David S. Boyer, MD
Updates from the Field
2025
Multiwavelength Photobiomodulation Significantly Reduces Risk for Vision Loss and Onset of Geographic Atrophy in Dry Age-Related Macular Degeneration
Eleonora Lad, MD, PhD
Updates from the Field
2024
Debate: How Should We Treat Geographic Atrophy
Ajay E Kuriyan, MD, MS
Updates from the Field
2024
Machine and Deep Learning (AI) Algorithms for GA Identification and Prediction of Progression to GA from Intermediate AMD: The Future of Dry AMD Management
Eleonora Lad, MD, PhD
Updates from the Field
2023
Dual Anti-platelet Therapy Decelerates the Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration
Yodpong Chantarasorn, MD
On Demand Cases, Courses, and Papers
2021
Treatment of Geographic Atrophy Secondary to AMD With Pegcetacoplan: Two-Year Outcomes From the Randomized Phase 3 DERBY and OAKS Trials
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2022
GATHER2 Phase 3 Efficacy Results and GATHER2 Phase 3 Safety Results
Jeffrey S. Heier, MD
Arshad M. Khanani, MD, MA, FASRS
Updates from the Field
2022